Deuterated camptotechcin compound, and preparation thereof and use thereof.

Deuterated camptothecin compounds address the toxicity issues of existing camptothecin-based drugs by enhancing plasma stability and reducing in vivo exposure, offering a safer and more effective treatment for tumors.

BR112025024216A2Pending Publication Date: 2026-11-10SHANGHAI QILU PHARMACEUTICAL RESEARCH & DEVELOPMENT CENTRE LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
BR112025024216
Authority / Receiving Office
BR · BR
Patent Type
Applications
Current Assignee / Owner
Priority Date
2024-04-29
Filing Date
2024-05-06
Publication Date
2026-11-10

AI Technical Summary

Technical Problem

Existing camptothecin-based drugs suffer from in vivo toxicity issues, limiting their application and efficacy in cancer treatment.

Method used

Development of deuterated camptothecin compounds and their pharmaceutically acceptable salts, which exhibit improved plasma stability, shorter half-life in vivo, and lower in vivo exposure, reducing toxicity when used as cancer therapeutic agents or payloads for antibody-drug conjugates.

Benefits of technology

The deuterated camptothecin compounds demonstrate lower toxicity and improved safety profiles, making them effective in treating tumors with reduced side effects.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

Disclosed are a deuterated camptothecin compound as represented by formula II and a pharmaceutically acceptable salt thereof, a preparation method therefor, a pharmaceutical composition containing the deuterated camptothecin compound or a pharmaceutically acceptable salt thereof, and the use thereof in the treatment of tumor-related diseases. Such deuterated camptothecin compound has excellent drug activity and pharmacokinetic properties, and has reduced in-vivo toxicity and improved in-vivo safety.
Need to check novelty before this filing date? Find Prior Art

Description

1 / 44 Deuterated camptotechcin compound, and preparation thereof and use thereof. CROSS-REFERENCE TO RELATED REQUESTS

[0001] This application claims the benefits and priorities of Chinese Patent Application No. 202310506357.6 filed with the National Intellectual Property Administration of China on May 6, 2023, Chinese Patent Application No. 202311533730.3 filed with the National Intellectual Property Administration of China on November 16, 2023, and Chinese Patent Application No. 202410535444.9 filed with the National Intellectual Property Administration of China on April 29, 2024, the entire content of which is incorporated herein by reference in its entirety. TECHNICAL FIELD

[0002] This disclosure pertains to the field of medicinal chemistry and relates specifically to a class of deuterated camptothecin compounds, pharmaceutically acceptable salts thereof, methods of preparation thereof, pharmaceutical compositions containing the deuterated camptothecin compounds or pharmaceutically acceptable salts thereof, and the use of the deuterated camptothecin compounds, pharmaceutically acceptable salts thereof, or pharmaceutical compositions in the treatment of tumor-related diseases. FUNDAMENTALS

[0003] Camptothecin (CPT) is a cytotoxic pyrroloquinoline alkaloid and one of the most extensively studied natural antitumor drugs besides paclitaxel. Camptothecin is found primarily in the fruits and root bark of Camptotheca acuminata, a plant in the Nyssaceae family that is unique to China. In 1985, Hsiang et al. discovered that camptothecin and its derivatives exert their anticancer effects by targeting topoisomerase I (topo I) to inhibit DNA synthesis. This revelation rekindled widespread interest, leading to the emergence of numerous derivatives and establishing them as a new focal point in anticancer research. Subsequently, a Petition 870250101738, dated 06 / 11 / 2025, page 12 / 273 2 / 44 A new generation of camptothecin-based drugs, such as 10-hydroxycamptothecin (HCPT), irinotecan, topotecan, SN-38, and belotecan, has been successively approved for marketing. These drugs are used to treat cancers such as colorectal cancer, small cell lung cancer, and ovarian cancer, with promising advances in their indications and formulations.

[0004] With the development of drug delivery systems, a number of camptothecin drugs that were previously unmedicinable or had significant side effects have regained application. However, the issue of in vivo toxicity associated with camptothecin drugs has not been entirely avoided. How to further reduce the toxicity of this class of drugs remains a problem that needs attention at present. SUMMARY

[0005] In one aspect, the present disclosure provides a compound of Formula II, a pharmaceutically acceptable salt thereof or a stereoisomer thereof: Formula II

[0006] characterized in that Ri is H, halogen, OH, SH, NH2, C1-4 alkyl, C1-4 haloalkyl or C1-4 alkoxy;

[0007] R2 is H, halogen, C1-4 alkyl or C1-4 alkoxy;

[0008] or R1 and R2 are cyclized to form -O-(CH2)mO-, where m is 1, 2 or 3;

[0009] R3 and R4 are each independently H, C1-4 alkyl, C1-4 alkoxy, C1-4 haloalkyl or C1-4 haloalkoxy;

[0010] or R3 and R4 are cyclized to form -(CH2)k-, where k is 1, 2, 3 or 4; Petition 870250101738, dated 06 / 11 / 2025, p. 13 / 273 3 / 44

[0011] X is H, OH, HO-CH(R5)-(CH2)p-CO-NH-, or -N(R6)(R7), where p is 0, 1 or 2;

[0012] R5 is H, C1-4 alkyl, C1-4 haloalkyl, 3- to 6-membered cycloalkyl or 3 to 6-membered heterocycloalkyl;

[0013] R6 is H, C1-4 alkyl or C1-4 haloalkyl;

[0014] R7 is H or R8-S(O)2-;

[0015] Rs is C1-4 alkyl; and

[0016] t is 0, 1, 2, 3, 4 or 5.

[0017] In this disclosure, the expression R1 and R2 are cyclized to form -O(CH2)mO- means that R1 and R2 are connected to form -O-(CH2)mO-. The expression R3 and R4 are cyclized to form -(CH2)k- means that R3 and R4 are connected to form -(CH2)k-.

[0018] In any embodiment of the compound of Formula II of the present disclosure, R1 is C1-4 alkyl and R2 is halogen.

[0019] In any embodiment of the compound of Formula II of this disclosure, R1 is methyl and R2 is F.

[0020] In any embodiment of the Formula II compound of this disclosure, R1 is H and R2 is H.

[0021] In any embodiment of the Formula II compound of this disclosure, R1 and R2 are cyclized to form -O-CH2-O-.

[0022] In any embodiment of the compound of Formula II of this disclosure, R1 is NH2 and R2 is H or halogen. In any embodiment of the compound of Formula II of this disclosure, R1 is NH2 and R2 is H or F.

[0023] In any embodiment of the Formula II compound of this disclosure, R3 is H and R4 is H.

[0024] In any embodiment of the compound of Formula II of this disclosure, R3 is H and R4 is C1-4 alkyl.

[0025] In any embodiment of the compound of Formula II of this disclosure, R3 is H and R4 is methyl.

[0026] In any embodiment of the Formula II compound of the present disclosure, R3 and R4 are cyclized to form -CH2-CH2-. Petition 870250101738, dated 06 / 11 / 2025, p. 14 / 273 4 / 44

[0027] In any embodiment of the compound of Formula II of this disclosure, X is HO-CH(R5)-(CH2) p-CO-NH-, where p is 0, 1 or 2.

[0028] In any embodiment of the compound of Formula II of this disclosure, X is OH or NH2.

[0029] In any embodiment of the Formula II compound of this disclosure, X is H and is 0.

[0030] In any embodiment of the Formula II compound of this disclosure, X is -N(R6)(R7).

[0031] In one embodiment of the compound of Formula II of the present disclosure, the compound of Formula II is a compound of Formula IIa, a pharmaceutically acceptable salt thereof or a stereoisomer thereof; Formula IIa

[0032] where Ri, R2, R3 and R4 are as defined in any embodiment of the Formula II compound; X1 is H or HO-CH(R5)-(CH2) p-CO-, where p is 0, 1 or 2; R5 is H, C1-4 alkyl, 3- to 6-membered cycloalkyl or 3 to 6-membered heterocycloalkyl.

[0033] In any embodiment of the compound of Formula IIa of this disclosure, Ri is methyl or methoxy; or Ri is methyl.

[0034] In any form of disclosure, R2 is F or Cl; or R2 is F.

[0035] In any form of disclosure, Ri is methyl and R2 is F.

[0036] In any embodiment of the compound of Formula IIa of this compound of Formula IIa of this compound of Formula IIa of this disclosure, R3 and R4 are cyclized to form -(CH2)k-, where k is 2.

[0037] In any embodiment of the compound of Formula IIa of this Petition 870250101738, dated 06 / 11 / 2025, p. 15 / 273 5 / 44 disclosure, R3 is H; and R4 is H.

[0038] In any embodiment of the compound of Formula Ila of the present disclosure, Xi is HO-CH(R5)-(CH2) p-CO-, where p is 0 or 1, and R5 is H, ci-4 alkyl, or cycloalkyl of 3 to 6 members.

[0039] In any embodiment of the compound of Formula IIa of this disclosure, Xi is HO-CH(R5)-(CH2)p-CO-, where p is 0 or 1, and R5 is H, methyl or cyclopropyl.

[0040] In any embodiment of the compound of Formula IIa of this disclosure, Xi is HO-CH(R5)-CO- and R5 is H or 3- to 6-membered cycloalkyl.

[0041] In any embodiment of the compound of Formula IIa of this disclosure, Xi is HO-CH(R5)-CO- and R5 is H or cyclopropyl.

[0042] In any embodiment of the compound of Formula IIa of this disclosure, xi is HO-CH(R5)-CH2-CO- and R5 is C1-4 alkyl.

[0043] In any embodiment of the compound of Formula IIa of this disclosure, X i is HO-CH(R5)-CH2-CO- and R5 is methyl.

[0044] In any embodiment of the compound of Formula IIa of this THE HO disclosure, Xi is the following group: H, '

[0045] In some embodiments of the compound of Formula IIa of the present disclosure, the compound of Formula IIa is the following compound of Formula IIa-1 or Formula IIa-2, a pharmaceutically acceptable salt thereof or a stereoisomer thereof; Petition 870250101738, dated 06 / 11 / 2025, p. 16 / 273 6 / 44 Formula IIa-1 Formula IIa-2

[0046] where Ri, R2 and Xi are as defined in any embodiment of the Formula IIa compound.

[0047] In some embodiments of the compound of Formula IIa of the present disclosure, the compound of Formula IIa is the following compound, a pharmaceutically acceptable salt thereof, or a stereoisomer thereof: Petition 870250101738, dated 06 / 11 / 2025, p. 17 / 273 7 / 44

[0048] In one embodiment of the compound of Formula II of the present disclosure, the compound of Formula II is a compound of Formula IIb, a pharmaceutically acceptable salt thereof or a stereoisomer thereof;

[0049] where Ri is H, OH, halogen, NH2, C1-4 alkyl, C1-4 haloalkyl or C1-4 alkoxy;

[0050] R2 is H, halogen, C1-4 alkyl or C1-4 alkoxy;

[0051] or R1 and R2 are cyclized to form -O-(CH2)mO-, where m is 1, 2 or 3;

[0052] R3 and R4 are each independently H, C1-4 alkyl or C1-4 alkoxy;

[0053] or R3 and R4 are cyclized to form -(CH2)k-, where k is 1, 2 or 3;

[0054] X2 is H, OH or -N(R6)(R7);

[0055] R6 is H or C1-4 alkyl;

[0056] R7 is H or R8-S(O)2-;

[0057] Rs is C1-4 alkyl; and

[0058] q is 0, 1, 2, 3 or 4.

[0059] In any embodiment of the compound of Formula IIa of the present disclosure, R1 is methyl and R2 is H, Cl, or F

[0060] In any embodiment of the Formula IIb compound of this Petition 870250101738, dated 06 / 11 / 2025, p. 18 / 273 8 / 44 disclosure, Ri and R2 are cyclized to form -O-(CH2)mO-, where m is 1 or 2.

[0061] In any disclosure modality, R3 and R4 are both H.

[0062] In any form of disclosure, R3 is H and R4 is methyl.

[0063] In any embodiment of the compound of Formula IIb of this compound of Formula IIb of this compound of Formula IIb of this disclosure, X2 is H, OH, NH2 or N(i-Pr)-S(O)2-CH3.

[0064] In any embodiment of the compound of Formula IIb of this disclosure, X2 is H eq is 0; or X2 is OH or -N(R6)(R7) eq is 0, 1, 2, 3 or 4.

[0065] In any embodiment of the compound of Formula IIb of this disclosure, X2 is OH or -N(R6)(R7); q is 1, 2, 3 or 4; R3 and R4 are both H; R1 is methyl, and R2 is H, Cl or F, or R1 and R2 are cyclized to form -O-(CH2)mO-, where m is 1 or 2.

[0066] In some embodiments of the compound of Formula IIb of this disclosure, the compound of Formula IIb is the following compound of Formula IIb-1 or Formula IIb-2;

[0067] in compounds of Formula IIb-1 and Formula IIb-2, R1, R2, X2 eq are as defined in any embodiment of the compound of Formula IIb.

[0068] In some embodiments of the compound of Formula IIb, the compound of Formula IIb is the following compound, a pharmaceutically acceptable salt thereof, or a stereoisomer thereof; Petition 870250101738, dated 06 / 11 / 2025, p. 19 / 273 9 / 44

[0069] In one embodiment of the present disclosure, the compounds of Formula II, Formula Ila, Formula IIb, Formula IIa-1, Formula IIb-1, Formula IIa-2 and Formula IIb-2 exclude the following compounds;

[0070] In another aspect, the present disclosure provides a pharmaceutical composition comprising the compound of Formula II, Formula IIa, Formula IIb, Formula IIa-1, Petition 870250101738, dated 06 / 11 / 2025, p. 20 / 273 10 / 44 Formula IIb-1, Formula IIa-2 or Formula IIb-2, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.

[0071] In yet another aspect, the present disclosure provides for the use of the compound of Formula II, Formula IIa, Formula IIb, Formula IIa-1, Formula IIb-1, Formula IIa-2 or Formula IIb-2, or a pharmaceutically acceptable salt thereof, or the pharmaceutical composition in the manufacture of a medicament for the treatment of tumors.

[0072] In yet another aspect, the present disclosure provides a method for treating tumors, comprising administering to a patient in need thereof an effective amount of the compound of Formula II, Formula IIa, Formula IIb, Formula IIa-1, Formula IIb-1, Formula IIa-2 or Formula IIb-2, or a pharmaceutically acceptable salt thereof, or the pharmaceutical composition.

[0073] In yet another aspect, the present disclosure provides the compound of Formula II, Formula IIa, Formula IIb, Formula IIa-1, Formula IIb-1, Formula IIa-2 or Formula IIb2, or a pharmaceutically acceptable salt thereof, or the pharmaceutical composition, for use in the treatment of tumors.

[0074] In yet another aspect, the present disclosure provides for the use of the compound of Formula II, Formula IIa, Formula IIb, Formula IIa-1, Formula IIb-1, Formula IIa-2 or Formula IIb-2, or a pharmaceutically acceptable salt thereof, or the pharmaceutical composition in the treatment of tumors.

[0075] It is well known to those skilled in the art that antibody-drug conjugates (ADCs) generally exhibit toxic effects due to the shedding of a small amount of payload in vivo. However, the compounds of the present disclosure, particularly Compound 2, show improved plasma stability, shorter half-life in vivo, and lower in vivo exposure. When used as an ADC payload, they are more readily eliminated after shedding in vivo, resulting in lower toxicity. Furthermore, toxicity tests of the present disclosure confirmed that the compounds of the present disclosure exhibit lower in vivo toxicity at equivalent doses. Whether used independently as cancer therapeutic agents or as payloads for ADC preparation, they all exhibit improved safety profiles. Petition 870250101738, dated 06 / 11 / 2025, page 21 / 273 11 / 44

[0076] Terms and descriptions

[0077] Unless otherwise specified, the terms used in this document have their general meanings in the technical field. A specific term or phrase without a specific definition should not be considered undefined or unclear, but should be understood according to its common meaning. When a trade name appears in this document, it is intended to refer to the corresponding trade name or its active ingredient.

[0078] In any embodiment of the compound of Formula II of this disclosure, when R1 and R2 are cyclized to form -O-(CH2)mO-, the compound of Formula II is the following compound of Formula II-1. In the present disclosure, in Formula II or in any of its embodiments, when R3 and R4 are cyclized to form -(CH2)k-, Formula II is presented in the form of the following Formula II-2.

[0079] The term Optionally or optionally means that the event or circumstance subsequently described may or may not occur and that the description includes instances where the event or circumstance occurs and instances where it does not occur. For example, the term optionally replaced means that a group may be either not replaced or replaced by the designated replacement; whether replaced or not, both are encompassed within the scope of optionally.

[0080] The term independently or each independently means that each of the aforementioned substituents in the term can select different optional variables from the specified range of choices and is not influenced by the selection results of other substituents. When a certain substituent that can be independent has a plurality of identical substituents in the overall chemical formula, Petition 870250101738, dated 06 / 11 / 2025, p. 22 / 273 12 / 44 he can still choose the same or different optional variables.

[0081] The term halogen or halogen atom refers to fluorine, chlorine, bromine, or iodine.

[0082] The term halo refers to a group formed by the substitution of one or more hydrogen atoms in a substituent by halogen atoms.

[0083] The term alkyl refers to a linear or branched hydrocarbon group in which carbon atoms are linked by single bonds. Alkyl is preferably C14 or C1-6 alkyl. C1-4 alkyl refers to a linear or branched alkyl group with 1, 2, 3, or 4 carbon atoms. Examples of C1-4 alkyl include, but are not limited to, methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, and tert-butyl. C1-6 alkyl refers to a linear or branched alkyl group with 1, 2, 3, 4, 5, or 6 carbon atoms. Examples of C1-6 alkyl groups include, but are not limited to: methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, n-pentyl, and n-hexyl.

[0084] The term haloalkyl refers to an alkyl group in which one or more hydrogen atoms are replaced by halogen atoms. Examples of C1-4 haloalkyl include, but are not limited to, trifluoromethyl, trichloromethyl, 2,2,2-trifluoroethyl, and 2,2,2-trichloroethyl.

[0085] The term alkoxy refers to alkyl-O-, where alkyl is as defined above, including C1-4 alkoxy or C1-6 alkoxy. C1-4 alkoxy can be understood as C1-4 alkyl-O-, examples of which include, but are not limited to, methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, sec-butoxy, and tert-butoxy. C1-6 alkoxy can be understood as C1-6 alkyl-O-, examples of which, in addition to the specific examples of C1-4 alkoxy mentioned above, include, but are not limited to, n-pentyloxy, neopentyloxy, n-hexyloxy, etc.

[0086] The term haloalkoxy refers to an alkoxy group in which one or more hydrogen atoms are replaced by halogen atoms. Examples of C1-4 haloalkoxy include, but are not limited to, trifluoromethoxy, trichloromethoxy, 2,2,2-trifluoroethoxy, and 2,2,2-trichloroethoxy.

[0087] The term cycloalkyl refers to a cyclic saturated monocyclic or polycyclic hydrocarbon group in which the carbon atoms are linked by bonds Petition 870250101738, dated 06 / 11 / 2025, p. 23 / 273 13 / 44 simple. The hydrogen atoms on the carbon atoms of the ring can optionally be replaced by oxo, that is, the -CH2- in the ring can optionally be replaced by oxo to form -C(O)-. 3- to 6-membered cycloalkyl refers to 3-, 4-, 5- or 6-membered cycloalkyl, specific examples of which include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl.

[0088] The term heterocycloalkyl refers to a cycloalkyl group in which one or more (e.g., 2, 3, or 4) carbon atoms of the ring are replaced by a heteroatom or a heteroatom group (i.e., a group containing a heteroatom). The carbon atoms in the ring refer to the carbon atoms that constitute the cyclic skeleton structure; the heteroatom refers to an atom other than C and H in organic compounds, such as nitrogen (N), oxygen (O), sulfur (S), phosphorus (P), or boron (B) atoms, wherein heteroatoms, such as nitrogen and sulfur atoms, can be oxidized and nitrogen atoms can be quaternized; Examples of the heteroatom group include, but are not limited to, -S(=O)2-, -S(=O)- and -NH-, optionally substituted -S(=O)(=NH)-, C(=O)NH-, -C(=NH)-, -S(=O)2NH-, S(=O)NH-, or -NHC(=O)NH-, etc.3- to 6-membered heterocycloalkyl refers to 3-, 4-, 5- or 6-membered heterocycloalkyl, with specific examples including, but not limited to, aziridinil, oxiranil, thiaranil, azetidinil, oxetanil, thietanil, pyrrolidinil, tetrahydrofuranil, thiolanil, piperazinil, piperidinil, tetrahydropyranil, morpholinil and 1,4-dioxanil.

[0089] The term composition is intended to include a product containing a specified amount of each of the specified ingredients, as well as any product derived directly or indirectly from a combination of the specified amount of each of the specified ingredients. Those skilled in the art may vary the actual dosage levels of the active ingredients in the pharmaceutical compositions of this disclosure so that the amount of active compound obtained is effective in achieving the desired therapeutic response for a specific patient, composition, and route of administration.

[0090] The term pharmaceutically acceptable refers to compounds, materials, compositions and / or dosage forms that are suitable for use in contact with Petition 870250101738, dated 06 / 11 / 2025, page 24 / 273 14 / 44 human and animal tissues without excessive toxicity, irritation, allergic reactions, or other problems or complications within the scope of reliable medical judgment and are proportionate to a reasonable benefit / risk ratio.

[0091] The term pharmaceutically acceptable salt refers to a salt of a pharmaceutically acceptable acid or base, including salts formed by the compound with inorganic or organic acids, as well as salts formed by the compound with inorganic or organic bases.

[0092] The term excipient generally refers to carriers, diluents and / or means necessary for the formulation of an effective pharmaceutical composition.

[0093] The term effective amount refers to an amount of the compound of this disclosure or a pharmaceutically acceptable salt thereof that is suitable for the treatment of a disease or condition with a reasonable benefit / risk ratio applicable to any medical treatment. The amount of the compound of this disclosure that constitutes an effective amount varies depending on the compound, the disease condition and its severity, the route of administration, and the age of the mammal to be treated, but can be routinely determined by one skilled in the art based on their own knowledge and the content of this disclosure.

[0094] In this disclosure, the symbol on a substituent indicates the attachment position of the substituent to the parent structure or other fragment. The appearance of a dash - on a substituent structure is used to indicate the attachment point of the substituent. For example, -CH3 indicates that the group is connected to the parent structure or other fragment through the C atom. ^ and -'' denote the absolute configuration of a stereocenter, i.e., R or S configuration.

[0095] In the present disclosure, the chemical bond represented by the solid and dashed line represents a single or double bond, which can be determined within the scope commonly known to those skilled in the art based on the valences of the atoms at both ends of the chemical bond.

[0096] In the present disclosure, the term isomer includes geometric isomers and stereoisomers, such as atropisomers, cis-trans isomers, enantiomers, diastereomers, tautomers and their racemic mixtures and other mixtures, all of which Petition 870250101738, dated 06 / 11 / 2025, page 25 / 273 15 / 44 fall within the scope of this disclosure. The term enantiomer refers to stereoisomers that are mirror images of each other. The term tautomer refers to a class of functional group isomers with different hydrogen bonding points through the displacement of one or more double bonds, for example, a ketone and its enol form are keto-enol tautomers. The term diastereomer refers to a stereoisomer in which the molecule has two or more chiral centers and the molecules are not mirror images of each other. The term cis-trans isomer refers to different spatial configurations in which double bonds or single bonds of ring carbon atoms in a molecule cannot rotate freely. The term atropisomer refers to stereoisomers that can be separated due to hindered or extremely slow rotation of single bonds.

[0097] Stereoisomers of the compounds in this disclosure can be prepared by chiral synthesis, chiral reagents, or other conventional techniques. For example, an enantiomer of a certain compound in this disclosure can be prepared by asymmetric catalytic techniques or chiral auxiliary derivatization techniques. Alternatively, a single stereoisomeric compound can be obtained from a mixture through chiral resolution techniques. Alternatively, a single stereoisomeric compound can be prepared directly using chiral starting materials. The separation of optically pure compounds in this disclosure is typically performed by preparative chromatography using a chiral chromatographic column to achieve the separation of chiral compounds.

[0098] In this disclosure, the solution concentration unit M represents mol / L, mM represents mmol / L, and nM represents nmol / L. The solution concentration unit N represents equivalent concentration, which is expressed as the number of equivalent grams of solute contained in 1 liter of solution, denoted by the symbol N. For example, if 1 liter of concentrated hydrochloric acid contains 12.0 equivalent grams of hydrochloric acid (HCl), its concentration is 12.0 N. Equivalent concentration = number of equivalent grams of solute / volume of solution (L).

[0099] The chemical abbreviations used in this disclosure and their corresponding chemical names are as follows: Petition 870250101738, dated 06 / 11 / 2025, p. 26 / 273 16 / 44 Chemical Abbreviation Chemical Name DBU 1,8-Diazabicyclo[5.4.0]undeco-7-ene HOBT 1-Hydroxybenzotriazole EDCI Carbodiimide DIPEA Diisopropylethylamine TCEP Tris(2-carboxyethyl)phosphine hydrochloride DME Ethylene glycol dimethyl ether DMTMM 4-(4,6-Dimethoxy-1,3,5-triazin-2-yl)-4-methylmorpholinium chloride MTBE Methyl tert-butyl ether

[0100] Example

[0101] The present disclosure is further illustrated in detail below by means of specific preparation examples and biological experiments. However, it should be understood that these examples and biological experiments are provided for illustrative purposes only and should not be construed as limiting the present disclosure in any way. It is clear to those skilled in the art that, unless otherwise specified, the materials used in this document are well known in the field, can be commercially purchased, or obtained by those skilled in the art based on published literature or conventional methods.Unless otherwise indicated, all reactions in this disclosure are carried out under continuous magnetic stirring in a dry nitrogen or argon atmosphere, using dry solvents, wherein: (i) temperatures are given in degrees Celsius (°C) and operations are carried out at room temperature, which generally refers to 15-35 °C, preferably 20-30 °C, and more preferably 20-25 °C; (ii) solvent removal is achieved by reduced pressure evaporation using a rotary evaporator, with a bath temperature not exceeding 60 °C; (iii) reaction progress is monitored by thin-layer chromatography (TLC); (iv) the final products exhibit satisfactory hydrogen nuclear magnetic resonance (1H-NMR) and / or mass spectrometry data. Petition 870250101738, dated 06 / 11 / 2025, page 27 / 273 17 / 44 (MS).

[0102] Example 1: Preparation of Compound 1

[0103] Step 1: L-1 L-2

[0104] 86.4 mL of 2,2,6,6-tetramethylpiperidine were added to a 3 L three-necked flask, followed by the addition of 1 L of anhydrous tetrahydrofuran. The system was cooled to -78°C and the reaction was carried out for 15 minutes. 272 ​​mL of a 2,5-Me n-butyllithium petroleum ether solution were added and the reaction was carried out for 30 minutes. 32 g of compound l-1 were dissolved in 200 mL of anhydrous tetrahydrofuran, then added to the system and the reaction was carried out for 1 hour. 50 mL of 1-penten3-one were dissolved in 200 mL of anhydrous tetrahydrofuran and then added to the system. The reaction was carried out for 1 hour. After the reaction was complete (monitored by TLC), 640 mL of 4 N hydrochloric acid were added and the mixture was extracted with ethyl acetate. The organic phases were combined, washed with saturated aqueous sodium bicarbonate solution, washed with saturated brine, and dried over anhydrous sodium sulfate.After the system was concentrated under vacuum, 21 g of compound L-2 were obtained by purification using column chromatography, with a yield of 49%. ESI-MS m / z: 253.68, [M+H]+.

[0105] 1H NMR (400 MHz, CDCh) δ 6.99 (s, 1H), 6.13 (dd, J = 17.3, 10.6 Hz, 1H), 5.29 (d, J = 7.0 Hz, 1H), 5.26 (s, 1H), 3.99 (s, 3H), 2.73 (s, 2H), 2.04 (dt, J = 14.8, 7.3 Hz, 1H), 1.98 - 1.87 (m, 1H), 0.91 (t, J = 7.3 Hz, 3H).

[0106] Step 2: Petition 870250101738, dated 06 / 11 / 2025, page 28 / 273 18 / 44

[0107] 21 g of compound L-2 were added to a 1 L three-necked flask, followed by the addition of 400 mL of anhydrous ethanol. The system was cooled to 0°C and then 14.21 g of sodium borodeuteride were added. The reaction mixture was stirred for 15 minutes and then heated to room temperature to react for 12 hours. After completion of the reaction (monitored by TLC), 30 mL of 1 N hydrochloric acid were added and the mixture was extracted with dichloromethane. The organic phases were combined, washed successively with saturated aqueous sodium bicarbonate solution and saturated brine, and dried over anhydrous sodium sulfate. After the system was concentrated under vacuum, 17 g of compound L-3 were obtained by purification by column chromatography as a clear viscous liquid, with a yield of 80%. ESI-MS m / z: 259.73, [M+H]+.1H NMR(400 MHz,CDCL) δ 6.99 (s, 1H), 6.13 (dd, J = 17.3, 10.6 Hz, 1H), 5.29 (d, J = 7.0 Hz, 1H), 5.26 (s, 1H), 3.99 (s, 3H), 2.73 (s, 2H), 2.04 (dt, J = 14.8, 7.3 Hz, 1H), 1.98 - 1.87 (m, 1H), 0.91 (t, J = 7.3 Hz, 3H).

[0108] Step 3:

[0109] 2 g of compound L-3 were added to a 250 mL round-bottom flask, followed by the addition of 100 mL of dichloromethane. The system was cooled to -78°C and ozone was introduced under these conditions. After the reaction was complete (monitored by TLC), 0.5 mL of dimethyl sulfide was added and the reaction mixture was heated to room temperature and stirred for 30 minutes. After the system was concentrated under vacuum, 1.9 g of compound L-4 was obtained by purification using column chromatography. Petition 870250101738, dated 06 / 11 / 2025, page 29 / 273 19 / 44 with a yield of 95%. The product was used directly in the next step, without further purification. ESI-MS m / z: 261.70, [M+H]+.

[0110] 1H NMR (400 MHz, CDCh) δ 7.15 (s, 1H), 5.19 (d, J = 4.8 Hz, 1H), 3.96 (s, 3H), 3.21 (d, J = 4.8 Hz, 1H), 2.64 (s, 1H), 1.80 (q, J = 7.5 Hz, 2H), 0.92 (t, J = 7.5 Hz, 3H).

[0111] Step 4:

[0112] 12 g of compound L-4 were added to a 1 L single-necked flask, followed by the addition of 240 mL of dichloromethane. The mixture was stirred for 30 minutes and the system was cooled to 0°C. 286 mg of 2,2,6,6-tetramethylpiperidine oxide, 616 mg of sodium bicarbonate, 654 mg of potassium bromide, and 18 mL of water were added, and the reaction mixture was stirred for 15 minutes. 120 mL of aqueous sodium hypochlorite solution (> 7.5% by weight) were added, and the reaction was carried out for 30 minutes. After the reaction was complete (monitored by TLC), 12 g of sodium bisulfite were added, and the mixture was extracted with dichloromethane. The organic phases were combined, washed with water, washed with saturated brine, and dried over anhydrous sodium sulfate. After the system was concentrated under vacuum, 6.6 g of compound L-5 were obtained by purification using column chromatography, with a yield of 55%. ESI-MS m / z: 259.68, [M+H]+.

[0113] 1H NMR (400 MHz, CDCh) δ 7.20 (s, 1H), 4.00 (s, 3H), 3.64 (s, 1H), 1.79 (q, J = 7.4 Hz, 2H), 0.97 (t, J = 7.4 Hz, 3H).

[0114] Step 5: Petition 870250101738, dated 06 / 11 / 2025, page 30 / 273 20 / 44

[0115] Under a carbon monoxide atmosphere, 3 g of compound L-5 were added to a 100 mL three-necked flask, followed by the addition of 286 mg of 1,3-bis(diphenylphosphamo)propane, 2.4 g of potassium carbonate, 129 mg of palladium acetate, 15 mL of N,N-dimethylformamide, and 30 mL of deuterated methanol. The system was heated to 65°C and the reaction was carried out for 12 hours. After the reaction was complete (monitored by TLC), 20 mL of 1 N hydrochloric acid were added and the mixture was extracted with ethyl acetate. The organic phases were combined, washed successively with saturated aqueous sodium bicarbonate solution and saturated brine, and dried over anhydrous sodium sulfate. After the system was concentrated under vacuum, 1.33 g of compound L-6 was obtained by purification using column chromatography, with a yield of 40%. ESI-MS m / z: 286.29, [M+H]+.

[0116] 1H NMR (400 MHz,CDCb) δ 7.98 (d, J = 2.0 Hz, 1H), 4.09 (d, J = 2.0 Hz, 3H), 3.71 (d, J = 2.6 Hz, 1H), 1.88 - 1.75 (m, 2H), 0.96 (td, J = 7.3, 1.9Hz, 3H).

[0117] Step 6:

[0118] 1 g of compound L-6 was added to a 50 mL two-necked flask, followed by the addition of 1.05 g of sodium iodide and 10 mL of acetonitrile. The system was cooled to 0°C and stirred for 30 minutes. 0.89 mL of trimethylsilyl chloride was added and the system was heated to room temperature to react for 12 hours. After the reaction was complete (monitored by TLC), 40 mL of water and 1 mL of aqueous solution were added. Petition 870250101738, dated 06 / 11 / 2025, p. 31 / 273 21 / 44 saturated sodium bisulfite was added and the mixture was stirred for 1 hour. The mixture was extracted with dichloromethane and dried over anhydrous sodium sulfate. After the system was concentrated under vacuum, 800 mg of compound L-7 was obtained by purification by column chromatography, with a yield of 84%. ESI-MS m / z: 272.27, [M+H]+.

[0119] 1H NMR (400 MHz, CDCL) δ 10.03 (s, 1H), 7.32 (s, 1H), 3.90 (s, 1H), 1.81 (dd, J = 14.5, 7.2 Hz, 2H), 0.99 (t, J = 7.4 Hz, 3H).

[0121] 620 mg of compound L-7 were added to a 25 mL two-necked flask, followed by the addition of 1.48 g of cesium carbonate, 8 mL of dimethyl sulfoxide, and 1.67 mL of tert-butyl acrylate. The system was heated to 65°C and the reaction was carried out for 12 hours. After the reaction was complete (monitored by TLC), 1 mL of concentrated hydrochloric acid was added, followed by the addition of 40 mL of water. The mixture was extracted with dichloromethane and dried over anhydrous sodium sulfate. After the system was concentrated under vacuum, 468 mg of compound L-8 were obtained by preparative SPC chiral separation (instrument model: SFC-350 (Waters), chromatographic column: AS 25 * 250 mm, 10 μm, mobile phase: CO2 / MeOH = 65 / 35, flow rate: 200 mL / min), with a yield of 55%. ESI-MS m / z: 365.38, [M+H]+.

[0122] Step 8:

[0123] 200 mg of compound L-8 were added to a 10-inch single-neck flask Petition 870250101738, dated 06 / 11 / 2025, page 32 / 273 22 / 44 mL, followed by the addition of 5 mL of toluene and 0.5 mL of trifluoroacetic acid. The system was heated to 110°C and the reaction was carried out for 2 hours. After the reaction was complete (monitored by TLC), the system was concentrated under vacuum and 140 mg of compound L-9 were obtained by purification by column chromatography, with a yield of 98%. ESI-MS m / z: 265.26, [M+H]+.

[0124] Step 9:

[0125] 300 mg of compound L-9 were added to a 25 mL single-neck flask, followed by the addition of 266 mg of N-(5-methyl-6-fluoro-8-amino-1-oxo-1,2,3,4-tetrahydronaphthalen-2-yl)acetamide, 9 mL of toluene, 770 mL of o-cresol, and 133 mg of pyridinium ptoluenesulfonate. The system was heated to 110°C and the reaction was carried out for 18 hours. After completion of the reaction (monitored by TLC), the system was concentrated under vacuum and 443 mg of compound L-10 were obtained by purification by column chromatography (dichloromethane:methanol = 10:1), with a yield of 81%.

[0126] Step 10:

[0127] 443 mg of intermediate compound L-10 were added to a 25 mL single-neck flask, followed by the addition of 7 mL of purified water and 2.2 mL of methanesulfonic acid. The system was purged with nitrogen. The system was heated to 85°C and the reaction was carried out for 10 hours. After the reaction was complete (monitored by Petition 870250101738, dated 06 / 11 / 2025, page 33 / 273 23 / 44 (TLC), the system was concentrated under vacuum and 141 mg of compound 1 were obtained by purification by column chromatography (dichloromethane: methanol), with a yield of 35%. ESI-MS m / z: 437.47, [M+H]+.

[0128] 1H NMR(400 MHz, D2O)δ 7.20 - 7.06 (m, 2H), 5.42 - 5.14 (m, 5H), 3.30 (dd, J = 18.1, 4.0 Hz, 1H), 3.06 - 2.91 (m, 1H), 2.69 (s, 2H), 2.62 - 2.47 (m, 1H), 2.18 (s, 3H), 1.80 (q, J = 7.3 Hz, 2H), 0.79 (t,J = 7.4 Hz, 3H).

[0129] Example 2: Preparation of Compound 2 2-1 2

[0130] 2.4 mL of water and 3.0 mL of tetrahydrofuran were added to a mixture of anhydrous sodium sulfate (2.25 eq), ethyl 2-cyano-2-hydroxyiminoacetate (2.25 eq), 2-hydroxyacetic acid (1.45 eq), and the methanesulfonate salt of compound 1 (100 mg). After stirring at room temperature for 15 minutes, N-methylmorpholine (1.10 eq) was added and the mixture was stirred at room temperature for 15 minutes. Subsequently, EDCI (2 eq) was added and the reaction mixture was stirred at room temperature for 3 hours. After complete reaction of compound 1 was monitored by HPLC, the reaction mixture was filtered and the filter cake was dried. The title compound was obtained by purification by silica gel column chromatography (DCM: MeOH).

[0131] 1H NMR (400 MHz, DMSO) δ 8.41 (d, J = 8.9 Hz, 1H), 7.77 (d, J = 11.0 Hz, 1H), 7.30 (s, 1H), 6.52 (s, 1H), 5.58 (d, J = 5.4 Hz, 1H), 5.49 (t, J = 5.7 Hz, 1H), 5.20 (t, J = 13.9 Hz, 2H), 3.96 (d, J = 5.5 Hz, 2H), 3.28 - 3.05 (m, 2H), 2.39 (s, 3H), 2.29 - 2.11 (m, 2H), 1.96 - 1.78 (m, 2H), 0.87 (t, J = 7.2 Hz, 3H). MS (ESI) m / z [M+H]+: 496.1.

[0132] Example 3: Preparation of Compound 3 Petition 870250101738, dated 06 / 11 / 2025, p. 34 / 273 24 / 44 3-1

[0133] With reference to the preparation method of Example 2, 52 mg of compound 3 were prepared using (R)-2-cyclopropyl-2-hydroxyacetic acid as starting material, with a yield of 52%.

[0134] 1H NMR (400 MHz, DMSO-d6) δ 8.36 (d, J = 8.4 Hz, 1H), 7.78 (d, J = 10.9 Hz, 1H), 7.31 (s, 1H), 6.52 (s, 0H), 5.58 - 5.48 (m, 1H), 5.38 (d, J = 5.3 Hz, 1H), 5.21 (q, J = 19.0 Hz, 2H), 3.62 (d, J = 5.2 Hz, 1H), 3.16 (dd, J = 11.2, 5.7 Hz, 3H), 2.39 (s, 4H), 2.22 - 2.12 (m, 3H), 1.86 (dt, J = 14.3, 7.1 Hz, 2H), 1.14 (q, J = 7.3 Hz, 2H), 0.87 (t, J = 7.2 Hz, 3H), 0.38 (dd, J = 20.9, 5.6 Hz, 4H). MS (ESI) m / z [M+H]+: 536.2.

[0135] Example 4: Preparation of Compound 4 4-1 4

[0136] Referring to the preparation method of Example 2, 54 mg of compound 4 were prepared using (S)-2-cyclopropyl-2-hydroxyacetic acid as starting material, with a yield of 54%.

[0137] 1H NMR (400 MHz, DMSO-d6) δ 8.37 (d, J = 9.0 Hz, 1H), 7.77 (d, J = 11.0 Hz, 1H), 7.30 (s, 1H), 6.51 (s, 1H), 5.58 (q, J = 6.7 Hz, 1H), 5.49 (d, J = 5.2 Hz, 1H), 5.35 Petition 870250101738, dated 06 / 11 / 2025, p. 35 / 273 25 / 44 5.06 (m, 2H), 3.60 (t, J = 5.7 Hz, 1H), 3.17 (q, J = 17.2 Hz, 2H), 2.39 (s, 3H), 2.16 (d, J = 6.1 Hz, 2H), 1.85 (dq, J = 14.2, 7.1 Hz, 2H), 1.24 (q, J = 8.1 Hz, 1H), 0.87 (t, J = 7.3 Hz, 3H), 0.59 - 0.32 (m, 4H). MS (ESI) m / z [M+H]+: 536.2.

[0138] Example 5: Preparation of Compound 5 5-1

[0139] With reference to the preparation method of Example 2, 55 mg of compound 5 were prepared using (R)-3-hydroxybutyric acid as starting material, with a yield of 56%.

[0140] 1H NMR (400 MHz, DMSO-d6) δ 8.42 (d, J = 8.7 Hz, 1H), 7.78 (d, J = 11.0 Hz, 1H), 7.30 (s, 1H), 6.52 (s, 1H), 5.55 (dt, J = 9.3, 5.0 Hz, 1H), 5.29 - 5.12 (m, 2H), 4.66 (d, J = 4.7 Hz, 1H), 4.05 (dt, J = 12.1, 6.0 Hz, 1H), 3.25 - 3.09 (m, 2H), 2.39 (s, 3H), 2.33 - 2.17 (m, 2H), 2.13 (dd, J = 10.7, 5.4 Hz, 2H), 1.86 (hept, J = 7.1 Hz, 2H), 1.09 (d, J = 6.2 Hz, 3H), 0.87 (t, J = 7.3 Hz, 3H). MS (ESI) m / z [M+H]+: 524.2.

[0141] Example 6: Preparation of Compound 6 6-1 6

[0142] With reference to the preparation method of Example 2, 51 mg of compound 6 were prepared using (6j-3-hydroxybutyric acid) as starting material, with a yield of 52%. Petition 870250101738, dated 06 / 11 / 2025, p. 36 / 273 26 / 44

[0143] 1H NMR (400 MHz, DMSO-d6) δ 8.41 (d, J = 8.7 Hz, 1H), 7.78 (d, J = 11.0 Hz, 1H), 7.30 (s, 1H), 6.53 (s, 1H), 5.57 (dt, J = 8.8, 4.5 Hz, 1H), 5.22 (d, J = 2.7 Hz, 2H), 4.64 (d, J = 4.5 Hz, 1H), 4.05 (dt, J = 11.9, 6.1 Hz, 1H), 3.16 (t, J = 5.7 Hz, 2H), 2.39 (s, 3H), 2.32 - 2.17 (m, 2H), 2.17 - 2.04 (m, 2H), 1.86 (hept, J = 7.1 Hz, 2H), 1.08 (d, J = 6.1 Hz, 3H), 0.87 (t, J = 7.3 Hz, 3H). MS (ESI) m / z [M+H]+: 524.2.

[0144] Example 7: Preparation of Compound 7 7-1 7-2 Compound 7

[0145] Compound 7-1 (87 mg, 1 eq), compound 7-2 (144 mg, 1.1 eq), pyridinium p-toluenesulfonate (50 mg, 0.4 eq), acetic acid (2.6 mL, 30 V), and toluene (2.6 mL, 30 V) were added to a reaction flask. The reaction was carried out at 110°C for 18 hours. After the reaction was complete (monitored by TLC), the solvent was removed by rotary evaporation. 123 mg of compound 7 were obtained by purification using silica gel column chromatography (dichloromethane:methanol), with a yield of 61%.

[0146] 1H NMR (400 MHz, DMSO-d6) δ 7.72 (d, J = 9.0 Hz, 1H), 7.29 (d, J = 9.0 Hz, 1H), 7.17 (s, 1H), 6.45 (s, 1H), 5.65 (s, 2H), 5.16 (s, 2H), 3.04 (t, J = 6.1 Hz, 2H), 2.75 (t, J = 6.1 Hz, 2H), 2.08 - 1.95 (m, 2H), 1.85 (hept, J = 7.1 Hz, 2H), 0.88 (t, J = 7.2 Hz, 3H). MS (ESI) m / z [M+H]+: 406.1.

[0147] Example 8: Preparation of Compound 8 Compound 8 8-1 7-2

[0148] Referring to the preparation method of Example 7, 127 mg of compound 8 Petition 870250101738, dated 06 / 11 / 2025, p. 37 / 273 27 / 44 were prepared using compounds 8-1 and 7-2 as starting materials, with a yield of 60%.

[0149] 1H NMR (400 MHz, DMSO-d6) δ 8.41 (d, J = 8.7 Hz, 1H), 7.78 (d, J = 11.0 Hz, 1H), 7.30 (s, 1H), 6.53 (s, 1H), 5.57 (dt, J = 8.8, 4.5 Hz, 1H), 5.22 (d, J = 2.7 Hz, 2H), 4.64 (d, J = 4.5 Hz, 1H), 4.05 (dt, J = 11.9, 6.1 Hz, 1H), 3.16 (t, J = 5.7 Hz, 2H), 2.39 (s, 3H), 2.32 - 2.17 (m, 2H), 2.17 - 2.04 (m, 2H), 1.86 (hept, J = 7.1 Hz, 2H), 1.08 (d, J = 6.1 Hz, 3H), 0.87 (t, J = 7.3 Hz, 3H). MS (ESI) m / z [M+H]+: 424.1.

[0150] Example 9: Preparation of Compound 9

[0151] Step 1: 9-1 7-2 9-3

[0152] 250 mg of compound 9-1, 300 mg of compound 7-2, 7.5 mL of acetic acid, 7.5 mL of toluene, and 68 mg of pyridinium p-toluenesulfonate were added to a 50 mL single-neck flask. The reaction was carried out at 110°C for 18 hours. After the reaction was complete (monitored by TLC), the solvent was evaporated under reduced pressure, and 386 mg of compound 9-3 were obtained by silica gel column chromatography (DCM:MeOH) purification, with a yield of 81%. MS (ESI) m / z [M+H]+: 480.2.

[0153] Step 2:

[0154] 380 mg of compound 9-3 were added to a 100 mL neck flask Petition 870250101738, dated 06 / 11 / 2025, page 38 / 273 28 / 44 single, followed by the addition of 7.6 mL of purified water and 3.8 mL of methanesulfonic acid. The reaction was carried out at 85°C for 10 hours under a nitrogen atmosphere. After the reaction was complete (monitored by TLC), the reaction mixture was cooled to room temperature and 22.8 mL of methanol were added. The mixture was stirred at room temperature for 2 hours, filtered, and the crude product was obtained. The crude product was purified by silica gel column chromatography (dichloromethane:methanol) to obtain 148 mg of compound 9, with a yield of 35%.

[0155] 1H NMR (400 MHz, D2O) δ 7.20-7.06 (m, 2H), 5.42-5.14 (m, 5H), 3.30 (dd, J = 18.1, 4.0 Hz, 1H), 3.06-2.91 (m, 1H), 2.69 (s, 2H), 2.62-2.47 (m, 1H), 2.18 (s, 3H), 1.80 (q, J = 7.3 Hz, 2H), 0.79 (t, J = 7.4 Hz, 3H). MS (ESI) m / z [M+H]+: 438.2.

[0156] Example 10: Preparation of Compound 10 10-1 7-2 Compound 10

[0157] Referring to the preparation method of Example 9, 70 mg of compound 10 were prepared using compound 10-1 and compound 7-2 as starting materials, with a yield of 34%.

[0158] 1H NMR (400 MHz, DMSO-d6) δ 8.32 (d, J = 8.4 Hz, 1H), 8.20 (dd, J = 8.4, 1.2 Hz, 1H), 7.93-7.84 (m, 1H), 7.79 (t, J = 7.6 Hz, 1H), 7.35 (s, 1H), 6.56 (s, 1H), 5.42 (s, 2H), 3.98 (p, J = 6.7 Hz, 1H), 3.50 (t, J = 8.0 Hz, 2H), 3.42-3.35 (m, 2H), 3.00 (s, 3H), 1.88 (hept, J = 7.3 Hz, 2H), 1.15 (d, J = 6.7 Hz, 6H), 0.88 (t, J = 7.3 Hz, 3H). MS (ESI) m / z [M+H]+: 514.2.

[0159] Example 11: Preparation of Compound 11 Petition 870250101738, dated 06 / 11 / 2025, p. 39 / 273 29 / 44 HO O NH2 7-2 11-1

[0160] Referring to the preparation method of Example 9, 80 mg of compound 11 were prepared using compound 11-1 and compound 7-2 as starting materials, with a yield of 37%.

[0161] 1H NMR (500 MHz, DMSO-d6) δ 0.88 (t, J = 7.25 Hz, 3H), 1.32 (t, J = 7.5 Hz, 3H), 1.85 (m, 2H), 3.11 (q, J = 7.5 Hz, 2H), 5.26 (s, 2H), 6.48(s, 1H), 7.23 (s, 1H), 7.41 (d, J = 10.0 Hz, 2H), 8.01 (d, J = 10.0 Hz, 1H), 10.3 (s, 1H). MS (ESI) m / z [M+H]+: 395.1.

[0162] Example 12: Preparation of Compound 12 12-1 7-2 12-3

[0163] 255 mg of compound 12-1, 300 mg of compound 7-2, 7.5 mL of acetic acid, 7.5 mL of toluene, and 68 mg of pyridinium p-toluenesulfonate were added to a 50 mL single-necked flask. The reaction was carried out at 110°C for 18 hours. After the reaction was complete (monitored by TLC), the solvent was evaporated under reduced pressure, and 330 mg of compound 12-3 were obtained by purification using silica gel column chromatography (DCM:MeOH), with a yield of 70%.

[0164] 1H NMR (400 MHz, DMSO-d6) δ 7.63 (s, 1H), 7.51 (s, 1H), 7.24 (s, 1H), 6.50 (s, 1H), 6.30 (s, 2H), 5.26 (s, 2H), 3.81 (d, J = 5.9 Hz, 2H), 3.22 (s, 2H), 1.98 (d, J = 6.7 Hz, 4H), 0.88 (t, J = 7.2 Hz, 3H). MS (ESI) m / z [M+H]+: 471.1. Petition 870250101738, dated 06 / 11 / 2025, page 40 / 273 30 / 44 Compound 12

[0165] 300 mg of intermediate compound 12-3 were dissolved in 15 mL of 10% sulfuric acid and the reaction was carried out at 110°C for 48 hours. After completion of the reaction (monitored by TLC), the mixture was neutralized by the addition of a saturated aqueous solution of sodium carbonate, extracted with dichloromethane, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to obtain a crude product. The crude product was purified by silica gel column chromatography (DCM:MeOH) to obtain 89 mg of compound 12, with a yield of 31%.

[0166] 1H NMR (400 MHz, DMSO-d6) δ 7.63 (s, 1H), 7.50 (s, 1H), 7.24 (s, 1H), 6.48 (s, 1H), 6.28 (s, 2H), 5.32-5.19 (m, 2H), 3.51-3.46 (m, 2H), 3.17-3.13 (m, 2H), 1.92 - 1.76 (m, 4H), 0.88 (t, J = 7.2 Hz, 3H). MS (ESI) m / z [M+H]+: 453.2.

[0167] Example 13: Preparation of Compound 13 Compound 13-1 Compound 7-2 Compound 13-3 Compound 13

[0168] Referring to the preparation method of Example 12, 74 mg of compound 13 were prepared using compound 13-1 and compound 7-2 as starting materials, with a two-step yield of 16%.

[0169] 1H NMR (400 MHz, DMSO-d6) δ 7.63 (s, 1H), 7.50 (s, 1H), 7.24 (s, 1H), 6.48 (s, Petition 870250101738, dated 06 / 11 / 2025, page 41 / 273 31 / 44 1H), 6.28 (s, 2H), 5.32-5.19 (m, 2H), 3.51-3.46 (m, 2H), 3.17-3.13 (m, 2H), 1.94 - 1.76 (m, 6H), 0.88 (t, J = 7.2 Hz, 3H). MS (ESI) m / z [M+H]+: 467.2.

[0170] Example 14: Preparation of Compound 14

[0171] Step 1: 14-1 7-2 14-3

[0172] 213 mg of compound 14-1, 300 mg of compound 7-2, 7.5 mL of acetic acid, 7.5 mL of toluene, and 68 mg of pyridinium p-toluenesulfonate were added to a 50 mL single-neck flask. The reaction was carried out at 110°C for 18 hours. After the reaction was complete (monitored by TLC), the solvent was removed by rotary evaporation and 300 mg of compound 14-3 were obtained by purification by silica gel column chromatography (DCM: MeOH), with a yield of 68%. MS (ESI) m / z [M+H]+: 443.1.

[0173] Step 2: 14-3 14-4

[0174] 300 mg of compound 14-3 were dissolved in 3 mL of N,N-dimethylformamide, followed by the addition of sodium azide (48 mg, 1.1 eq). The reaction was carried out at 80°C for 16 hours. After the reaction was complete (monitored by TLC), the reaction mixture was cooled to room temperature and 18 mL of water were added. The mixture was extracted with ethyl acetate and the organic phases were combined. The organic phase Petition 870250101738, dated 06 / 11 / 2025, page 42 / 273 32 / 44 was washed with water, dried over anhydrous sodium sulfate, filtered and rotary evaporated to dryness to obtain 186 mg of crude compound 14-4, with a yield of 63%. MS (ESI) m / z [M+H]+: 436.1.

[0175] Step 3: 14-4

[0176] 186 mg of compound 14-4 were dissolved in 4 mL of tetrahydrofuran, followed by the addition of triphenylphosphine (134 mg, 1.2 eq). The reaction mixture was stirred at room temperature for 4 hours. After completion of the reaction (monitored by TLC), hydrochloric acid (4 M, 1 mL) was added to the reaction system and the mixture was reacted at 55°C for 16 hours. After concentration under reduced pressure, the residue was purified by a reversed-phase column (SEPA FLASH SW025, Spherical C18, 20-45 μm, 100 Å; mobile phase A: 0.05% formic acid / water, mobile phase B: acetonitrile; mobile phase A: mobile phase B = 40:60, flow rate of 20 mL / min) to obtain 63 mg of compound 14, with a yield of 35%.

[0177] 1H NMR (400 MHz, DMSO-d6) δ 8.62 (s, 2H), 8.45 (s, 1H), 7.50 (s, 1H), 7.25 (s, 1H), 6.48 (s, 1H), 6.28 (s, 2H), 5.41 (s, 2H), 5.20 (s, 2H), 4.70 (d, J = 6.0 Hz, 2H), 1.86 (tt, J = 14.2, 6.1 Hz, 2H), 0.88 (t, J = 7.2 Hz, 3H). MS (ESI) m / z [M+H]+: 424.1.

[0178] Example 15: Preparation of Compound 15 NH· D Petition 870250101738, dated 06 / 11 / 2025, page 43 / 273 33 / 44

[0179] With reference to the preparation method of Example 14, 50 mg of compound 15 were prepared using compounds 15-1 and 7-2 as starting materials, with a three-step yield of 11%.

[0180] 1H NMR (400 MHz, DMSO-d6) δ 8.62 (s, 2H), 8.45 (s, 1H), 7.50 (s, 1H), 7.25 (s, 1H), 6.48 (s, 1H), 6.28 (s, 2H), 5.41 (s, 2H), 5.20 (s, 2H), 3.51-3.46 (m, 2H), 3.17-3.13 (m, 2H), 1.86 (tt, J = 14.2, 6.1 Hz, 2H), 0.88 (t, J = 7.2 Hz, 3H). MS (ESI) m / z [M+H]+: 438.2.

[0181] Example 16: Preparation of Compound 16 16-1 7-2 16-3

[0182] 1 g of compound 16-1, 1.5 g of compound 7-2, 30 mL of acetic acid, 30 mL of toluene, and 340 mg of pyridinium p-toluenesulfonate were added to a 250 mL single-neck flask. The reaction was carried out at 110°C for 18 hours. After completion of the reaction (monitored by TLC), the solvent was removed by rotary evaporation and the target intermediate compound 16-3 (1.6 g) was obtained by purification by silica gel column chromatography (dichloromethane:methanol), with a yield of 75%. MS (ESI) m / z [M+H]+: 431.1.

[0183] 1.6 g of compound 16-3 was dissolved in 16 mL of N,N-dimethylformamide, followed by the addition of sodium azide (256 mg, 1.1 eq). The reaction was carried out at 80°C. Petition 870250101738, dated 06 / 11 / 2025, page 44 / 273 34 / 44 for 16 hours. After the reaction was complete (monitored by TLC), the reaction mixture was cooled to room temperature and 96 mL of water were added. The mixture was extracted with ethyl acetate and the organic phases were combined. The organic phase was washed with water, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to obtain 1.1 g of the crude compound 16-4, with a yield of 68%. MS (ESI) m / z [M+H]+: 438.2.

[0184] 1.1 g of compound 16-4 was dissolved in 22 mL of tetrahydrofuran, followed by the addition of triphenylphosphine (0.79 g, 1.2 eq). The mixture was stirred at room temperature for 4 hours. After the reaction was complete (monitored by TLC), hydrochloric acid (4 M, 5 mL) was added to the reaction system and the reaction was carried out at 55°C for 16 hours. The reaction mixture was concentrated under reduced pressure and purified by a reversed-phase column (instrument model: SEPA FLASH SW025, chromatographic column: Spherical C18, 20-45 μm, 100 Å, mobile phase A: 0.05% formic acid / water, mobile phase B: acetonitrile; mobile phase A: mobile phase B = 45:55, flow rate: 20 mL / min) to obtain 0.58 g of compound 16, with a yield of 56%.

[0185] 1H NMR (400 MHz, DMSO-d6) δ 8.62 (s, 3H), 8.43 (d, J = 8.0 Hz, 1H), 7.99 (d, J = 10.7 Hz, 1H), 7.35 (s, 1H), 5.59 (s, 2H), 4.70 (d, J = 6.0 Hz, 2H), 2.55 (s, 3H), 1.88 (hept, J = 7.1 Hz, 2H), 0.88 (t, J = 7.3 Hz, 3H). MS (ESI) m / z [M+H]+: 412.2.

[0186] Example 17: Preparation of Compound 17 Petition 870250101738, dated 06 / 11 / 2025, p. 45 / 273 35 / 44 2-1

[0187] 2.4 mL of water and 3.0 mL of tetrahydrofuran were added to a mixture of anhydrous sodium sulfate (2.25 eq), 2-hydroxyacetic acid (1.45 eq), and compound 16 (100 mg). After stirring at room temperature for 15 minutes, N-methylmorpholine (1.10 eq) was added and the mixture was stirred at room temperature for 15 minutes. Subsequently, EDCI (2 eq) was added and the reaction mixture was stirred at room temperature for 3 hours. After the complete reaction of compound 16 was monitored by HPLC, the mixture was extracted with dichloromethane, dried over anhydrous sodium sulfate, and filtered. The solvent was removed by rotary evaporation, and 82 mg of compound 17 were obtained by purification by silica gel column chromatography (DCM:MeOH), with a yield of 72%.

[0188] 1H NMR (400 MHz, DMSO) δ 8.41 (d, J = 8.9 Hz, 1H), 7.77 (d, J = 11.0 Hz, 1H), 7.30 (s, 1H), 6.52 (s, 1H), 5.58 (d, J = 5.4 Hz, 1H), 5.49 (t, J = 5.7 Hz, 1H), 5.20 (t, J = 13.9 Hz, 2H), 3.96 (d, J = 5.5 Hz, 2H), 2.55 (s, 3H), 1.96 - 1.78 (m, 2H), 0.87 (t, J = 7.2 Hz, 3H). MS (ESI) m / z [M+H]+: 470.2.

[0189] Example 18: Preparation of Compound 18 3-1 ho y OH Petition 870250101738, dated 06 / 11 / 2025, p. 46 / 273 36 / 44

[0190] Referring to the preparation method of Example 17, 78 mg of compound 18 were prepared using compound 3-1 and compound 16 as starting materials, with a yield of 63%.

[0191] 1H NMR (400 MHz, DMSO-d6) δ 8.36 (d, J = 8.4 Hz, 1H), 7.78 (d, J = 10.9 Hz, 1H), 7.31 (s, 1H), 6.52 (s, 0H), 5.58 - 5.48 (m, 1H), 5.38 (d, J = 5.3 Hz, 1H), 5.21 (q, J = 19.0 Hz, 2H), 3.62 (d, J = 5.2 Hz, 1H), 2.39 (s, 4H), 1.86 (dt, J = 14.3, 7.1 Hz, 2H), 1.14 (q, J = 7.3 Hz, 2H), 0.87 (t, J = 7.2 Hz, 3H), 0.38 (dd, J = 20.9, 5.6 Hz, 4H). MS (ESI) m / z [M+H]+: 510.2.

[0192] Example 19: Preparation of Compound 19 4-1 16 19

[0193] Referring to the preparation method of Example 17, 74 mg of compound 19 were prepared using compound 4-1 and compound 16 as starting materials, with a yield of 60%.

[0194] 1H NMR (400 MHz, DMSO-d6) δ 8.37 (d, J = 9.0 Hz, 1H), 7.77 (d, J = 11.0 Hz, 1H), 7.30 (s, 1H), 6.51 (s, 1H), 5.58 (q, J = 6.7 Hz, 1H), 5.49 (d, J = 5.2 Hz, 1H), 5.35 5.06 (m, 2H), 3.60 (t, J = 5.7 Hz, 1H), 2.39 (s, 3H), 1.85 (dq, J = 14.2, 7.1 Hz, 2H), 1.24 (q, J = 8.1 Hz, 1H), 0.87 (t, J = 7.3Hz, 3H), 0.59 - 0.32 (m, 4H). MS (ESI) m / z [M+H]+: 510.2.

[0195] Example 20: Preparation of Compound 20 Petition 870250101738, dated 06 / 11 / 2025, p. 47 / 273 37 / 44 5-1 16 20

[0196] Referring to the preparation method of Example 17, 70 mg of compound 20 were prepared using compound 5-1 and compound 16 as starting materials, with a yield of 58%.

[0197] 1H NMR (400 MHz, DMSO-d6) δ 8.42 (d, J = 8.7 Hz, 1H), 7.78 (d, J = 11.0 Hz, 1H), 7.30 (s, 1H), 6.52 (s, 1H), 5.55 (dt, J = 9.3, 5.0 Hz, 1H), 5.29 - 5.12 (m, 2H), 4.66 (d, J = 4.7 Hz, 1H), 4.05 (dt, J = 12.1, 6.0 Hz, 1H), 2.39 (s, 3H), 2.13 (dd, J = 10.7, 5.4 Hz, 2H), 1.86 (hept, J = 7.1 Hz, 2H), 1.09 (d, J = 6.2 Hz, 3H), 0.87 (t, J = 7.3 Hz, 3H). MS (ESI) m / z [M+H]+: 498.2.

[0198] Example 21: Preparation of Compound 21 6-1 16 21

[0199] Referring to the preparation method of Example 17, 75 mg of compound 21 were prepared using compound 6-1 and compound 16 as starting materials, with a yield of 62%.

[0200] 1H NMR (400 MHz, DMSO-d6) δ 8.41 (d, J = 8.7 Hz, 1H), 7.78 (d, J = 11.0 Hz, 1H), 7.30 (s, 1H), 6.53 (s, 1H), 5.57 (dt, J = 8.8, 4.5 Hz, 1H), 5.22 (d, J = 2.7 Hz, 2H), Petition 870250101738, dated 06 / 11 / 2025, p. 48 / 273 38 / 44 4.64 (d, J = 4.5 Hz, 1H), 4.05 (dt, J = 11.9, 6.1 Hz, 1H), 2.39 (s, 3H), 2.17 - 2.04 (m, 2H), 1.86 (hept, J = 7.1 Hz, 2H), 1.08 (d, J = 6.1 Hz, 3H), 0.87 (t, J = 7.3 Hz, 3H). MS (ESI) m / z [M+H]+: 498.2.

[0201] Biological activity test

[0202] 1. Detection of in vitro antitumor activity of the payload compounds of this disclosure

[0203] Objective: To detect the in vitro inhibitory activity of the compounds in this disclosure against NCI-N87 (human gastric cancer cells), Calu-3 (human lung adenocarcinoma cells), MDA-MB-453 (human breast cancer cells), KPL-4 (human breast cancer cells) or MDA-MB-468 (human breast cancer cells).

[0204] Tumor cells in the logarithmic growth phase, including NCI-N87 (source: ATCC, catalog number: CRL-5822), Calu-3 (source: ATCC, catalog number: HTB-55), MDA-MB-453 (source: ATCC, catalog number: HTB-131), KPL4 (source: Nanjing Cobioer Biosciences, catalog number: CBP60379) or MDA-MB468 (source: ATCC, catalog number: HTB-132), were seeded in cell plates at a density of 5,000 cells / well. The cell plates were then incubated in a CO2 cell culture incubator at 37°C, 5% for 12-16 hours. 100 μL of sample (starting at 10 μM, 4-fold dilution, 10 concentrations) were added to each well. After gentle shaking, the plates were placed in the incubator for further incubation. After 48 hours of incubation, 70 pL of CellTiter-Glo™ working solution (Promega, catalog number: G7572) were added, gently shaken to lyse the cells, and the plates were read on a microplate reader.The cell proliferation inhibition rate was calculated using the following formula: cell proliferation inhibition rate = (sample 1 well / control well) x 100%. GraphPad Prism 8.0 software was used to plot the Log value of the sample concentration as the x-axis and % cytotoxicity as the y-axis. Data were analyzed by non-linear regression (curve fitting) to obtain IC50 values ​​for each sample, with specific results presented in Tables 1-1 and 1-2.

[0205] Table 1-1. Results of the in vitro activity test of the compounds in the present Petition 870250101738, dated 06 / 11 / 2025, page 49 / 273 39 / 44 disclosure Compound NCI-N87 Calu-3 MDA- MB-453 MDA- MB-468 IC50 (nM) IC50 (nM) IC50 (nM) IC50 (nM) 2 7.17 27.15 114.5 0.98 3 4.37 17.13 40.27 0.97 4 4.06 19.32 55.34 0.88 5 9.18 32.9 94.6 1.3 6 13.35 46.63 121.1 3.11

[0206] Table 1-2. Results of the in vitro activity test of the compounds in this disclosure. Compound NCI-N87 KPL-4 MDA-MB-468 IC50 (nM) IC50 (nM) IC50 (nM) 12 7.29 7.05 1.7

[0207] Experimental results show that the compounds in this disclosure exhibit significant proliferation inhibitory activity against NCI-N87, Calu-3, MDAMB-453, KPL-4 or MDA-MB-468.

[0208] 2. Pharmacokinetics of the compounds in this disclosure in mice

[0209] Objective: To evaluate the pharmacokinetic characteristics of the compounds in this disclosure in mice.

[0210] Balb / c mice were taken, with 12 mice per group (half male and half female), randomly grouped and administered a single injection of the sample (Formulation A: 5% DMSO + 95% (15% sulfobutyl-β-cyclodextrinα normal saline), Formulation B: 5% DMSO-10% Solutol HS 15-85% normal saline, diluted according to dose). Blood samples were collected at cross-time points, including before administration and 5 min, 30 min, 1 h, 2 h, 4 h, 6 h, 8 h, 10 h and 24 h after administration. Plasma was collected and the concentration of the sample in plasma was detected by LC-MS. The parameters Petition 870250101738, dated 06 / 11 / 2025, page 50 / 273 40 / 44 pharmacokinetics were calculated and the results are shown in Table 2-1.

[0211] Table 2-1. PK parameters of the compounds in this disclosure in mice Mouse PK compound (IV, 3 mpk) T1 / 2 (h) Cmax (ng / mL) Formulation Dxd 1.17 521 A 2 0.455 449 A 3 0.607 4305 B 5 0.674 3515 B 6 0.679 2582.5 B

[0212] Experimental results show that the compounds in this disclosure exhibit a short half-life in vivo in mice. When these compounds are used as payloads for ADCs, in the event of ADC payload release in vivo, the payload is able to be rapidly eliminated in vivo, thus exhibiting superior in vivo safety.

[0213] 3. Pharmacokinetics of the compounds in rats

[0214] Objective: To evaluate the pharmacokinetic characteristics of the compounds in this disclosure in rats.

[0215] SD rats (acquired from Beijing Vital River Laboratory Animal Technology Co., Ltd.) were used, with 6 rats per group (half male and half female), randomly grouped. A single injection of the sample (Formulation A: 5% DMSO + 95% (15% sulfobutyl-P-cyclodextrin-normal saline), diluted according to the dose) was administered. Blood samples were collected at cross-time points: before administration and 5 min, 30 min, 1 h, 2 h, 4 h, 6 h, 8 h, 10 h and 24 h after administration. Plasma was collected and the concentration of the sample in plasma was detected by LC-MS. Pharmacokinetic parameters were calculated and the results are shown in Table 3-1.

[0216] Table 3-1. PK parameters of the compounds of this disclosure in rats Rat PK compound (IV, 3 mpk) Petition 870250101738, dated 06 / 11 / 2025, page 51 / 273 41 / 44 T1 / 2 (h) Cmax (ng / mL) AUCinf (h*ng / mL) Cl (mL / h / kg) Formulation Dxd 1.172 621.2 352.1 8629.5 A 2 0.661 406.2 217.7 14072.1 A

[0217] Experimental results show that the compounds in this disclosure also exhibit a short in vivo half-life and a rapid in vivo clearance rate in rats.

[0218] 4. In vitro plasma stability of the compounds in this disclosure

[0219] 398 μL of plasma were withdrawn and pre-warmed to 37°C, then co-incubated for 15 minutes. 2 pL of the sample solution were added to the plasma to prepare a final sample concentration of 5 μM. The above solution was co-incubated at 37°C and 50 pL aliquots were taken at 0, 15, 30, 60, and 120 minutes, followed by the addition of 450 pL of ice-cold acetonitrile (containing the internal standard). The solution was vortexed for 10 minutes, centrifuged, and the remaining parental substrate content was detected by the LC-MS / Ms method. For specific results, see Table 41.

[0220] Table 4-1. Plasma stability of the compounds in this disclosure Compound Residual content of the original toxin at 120 minutes (relative to 0 minutes) Human plasma Mouse plasma CD1 Dxd 87.57% 95.42% 2 111.04% 102.54% 3 105.54% 104.97% 5 107.73% 96.02% 6 94.89% 105.93%

[0221] Experimental results show that the compounds in this disclosure exhibit good plasma stability.

[0222] 5. Repeated administration toxicity experiments with the compounds of Petition 870250101738, dated 06 / 11 / 2025, page 52 / 273 42 / 44 present disclosure in rats

[0223] Test sample preparation: The test sample was weighed according to the predetermined weight in a glass vial. First, 1 mL of DMSO was added and mixed until the test sample was dissolved, followed by the addition of 1 mL of Solutol HS-15. After mixing thoroughly, 8 mL of sodium chloride injection were added and vortexed to obtain a clear, transparent solution.

[0224] SD rats (acquired from Beijing Vital River) were used as test animals. Compound 2 and the positive control Dxd were administered via tail vein injection for 7 consecutive days, with Compound 2 and the positive control Dxd set at two doses of 0.3 mg / kg and 1.0 mg / kg. During the acclimation period, cage-side observation was conducted daily; during the administration period, all animals underwent clinical observation twice daily (morning and afternoon). Reactions were recorded in various aspects, including skin, fur, eyes (sclera), ears, nose, oral cavity, thorax, abdomen, urogenital area, limbs, as well as respiration, movement, urination, defecation (including urine and stool color), and behavioral changes. Daily weight data for animals in the main test group were documented. For animals scheduled for dissection, terminal body weight (fasted) was measured before dissection.The food intake of the test animals was also recorded. The specific experimental results are shown in Table 5-1.

[0225] Table 5-1. Results of repeated-dose toxicity experiments of the compounds of this disclosure in rats Observation Indicators Test Results Dxd Control Group Compound 2 Group Clinical Observation Main Test Group + TK Group: Dxd: 0.3 mpk dose group: 31% (5 / 16) animals showed Main Test Group + TK Group: Compound 2: 0.3 mpk dose group: 13% (2 / 16) animals Petition 870250101738, dated 06 / 11 / 2025, page 53 / 273 43 / 44 Ataxia immediately after administration, among which 40% (2 / 5) died during recovery and the other rats recovered gradually; Dxd: 1 mpk dose group: 31% (5 / 16) animals showed ataxia immediately after administration, among which 40% (2 / 5) died during recovery and the other rats recovered gradually; showed ataxia immediately after administration, then recovered gradually; Compound 2: 1 mpk dose group: 25% (4 / 16) animals showed ataxia immediately after administration, then recovered gradually; Body weight, food intake Slow weight gain / loss; Decreased food intake At the same dose, the effects of Compound 2 and Dxd on rat body weight and food intake were generally comparable; For rats, the average food intake in the Compound 2 group was higher than in the control group at the same dose;

[0226] where $ represents male and Ç represents female.

[0227] At the end of administration, gross dissection was performed on D8 post-administration. Focal / speckled dark red discoloration was observed in the lungs of some deceased rats in the Dxd control group, while such pathological changes were not found in any dose group of compound 2.

[0228] The experimental data above show that compound 2 of the present disclosure exhibits lower in vivo toxicity and superior in vivo safety compared to Petition 870250101738, dated 06 / 11 / 2025, page 54 / 273 44 / 44 positive control Dxd.

[0229] In this disclosure, the comparative compound Dxd refers to the following compound, which can be prepared in accordance with the published literature. WO2014057687A. Dxd compound. Petition 870250101738, dated 06 / 11 / 2025, page 55 / 273

Claims

1 / 7 CLAIMS 1. Compound of Formula II, a pharmaceutically acceptable salt thereof or a stereoisomer thereof: Formula II characterized in that Ri is H, halogen, OH, SH, NH2, C1-4 alkyl, C1-4 haloalkyl or C1-4 alkoxy; R2 is H, halogen, C1-4 alkyl or C1-4 alkoxy; or R1 and R2 are cyclized to form -O-(CH2)mO-, where m is 1, 2 or 3; R3 and R4 are each independently H, C1-4 alkyl, C1-4 alkoxy, C1-4 haloalkyl or C1-4 haloalkoxy; or R3 and R4 are cyclized to form -(CH2)k-, where k is 1, 2, 3 or 4; X is H, OH, HO-CH(R5)-(CH2)p-CO-NH-, or -N(R6)(R7), where p is 0, 1, or 2; R5 is H, C1-4 alkyl, C1-4 haloalkyl, 3- to 6-membered cycloalkyl, or 3- to 6-membered heterocycloalkyl; R6 is H, C1-4 alkyl, or C1-4 haloalkyl; R7 is H or R8-S(O)2-; Rs is C1-4 alkyl; et is 0, 1, 2, 3, 4, or 5; and the compound of Formula II excludes any of the following compounds: Petition 870250101738, dated 06 / 11 / 2025, p. 56 / 273 2 / 7 2. A compound, pharmaceutically acceptable salt thereof or stereoisomer thereof, according to claim 1, characterized in that Ri is C1-4 alkyl and R2 is halogen; or Ri is methyl and R2 is F; or Ri is H and R2 is H; or Ri and R2 are cyclized to form -O-CH2-O-; or Ri is NH2 and R2 is H or halogen; or Ri is NH2 and R2 is H or F.

3. A compound, pharmaceutically acceptable salt thereof or stereoisomer thereof, according to claim 1 or 2, characterized in that R3 is H and R4 is H; or R3 is H and R4 is C1-4 alkyl; or R3 is H and R4 is methyl; or R3 and R4 are cyclized to form -CH2-CH2-.

4. A compound, a pharmaceutically acceptable salt thereof, or a stereoisomer thereof, according to any one of claims 1 to 3, characterized in that X is HO-CH(R5)-(CH2)p-CO-NH-, ep is 0, 1, or 2; or X is OH or NH2; or X is H, et is 0; or X is -N(R6)(R7).

5. Compound, pharmaceutically acceptable salt thereof or stereoisomer thereof, according to any one of claims 1 to 3, characterized in that the compound of Formula II is a compound of Formula IIa, a pharmaceutically acceptable salt thereof or a stereoisomer thereof: Petition 870250101738, dated 06 / 11 / 2025, page 57 / 273 3 / 7 Formula IIa where Ri, R2, R3 and R4 are as defined in any one of claims 1 to 3, and Xi is H, HO-CH(R5)-(CH2) p-CO-, where p is 0, 1 or 2; R5 is H, C1i-4 alkyl, 3 to 6 membered cycloalkyl or 3 to 6 membered heterocycloalkyl.

6. A compound, a pharmaceutically acceptable salt thereof or a stereoisomer thereof, according to claim 5, characterized in that R1 is methyl or methoxy; or R1 is methyl.

7. A compound, a pharmaceutically acceptable salt thereof or a stereoisomer thereof, according to claim 5 or 6, characterized in that R2 is F or Cl; or R2 is F.

8. A compound, a pharmaceutically acceptable salt thereof or a stereoisomer thereof, according to claim 5, characterized in that R1 is methyl and R2 is F.

9. A compound, pharmaceutically acceptable salt thereof, or a stereoisomer thereof, according to any one of claims 5 to 8, characterized in that R3 and R4 are cyclized to form -(CH2)k-, where k is 2; or R3 is H, and R4 is H.

10. Compound, pharmaceutically acceptable salt thereof, or stereoisomer thereof, according to any one of claims 5 to 9, characterized in that Xi is HO-CH(R5)-(CH2)p-CO-, p is 0 or 1, and R5 is H, C1-4 alkyl, or cycloalkyl of 3 to 6 members; or Xi is HO-CH(R5)-(CH2)p-CO-, p is 0 or 1, and R5 is H, methyl, or cyclopropyl; or Xi is HO-CH(R5)-CO-, and R5 is H or cycloalkyl of 3 to 6 members; or Xi is HO-CH(R5)-CO-, and R5 is H or cyclopropyl; or Xi is HO-CH(R5)-CH2-CO-, and R5 is C1-4 Petition 870250101738, dated 06 / 11 / 2025, page. 58 / 273 4 / 7 alkyl; or Xi is HO-CH(R5)-CH2-CO-, and R5 is methyl; or Xi is the following group: H, ? O HOΟΆ^ζ? HO , or 11. Compound, pharmaceutically acceptable salt thereof or stereoisomer thereof, according to any one of claims 5 to 10, characterized in that the compound of Formula IIa is a compound of Formula IIa-1 or Formula IIa-2, a pharmaceutically acceptable salt thereof or a stereoisomer thereof; wherein Ri, R2 and Xi are as defined in any one of claims 5 to 8 and 10.

12. Compound, pharmaceutically acceptable salt thereof or stereoisomer thereof, according to any one of claims 1 to 3, characterized in that the compound of Formula II is a compound of Formula IIb, a pharmaceutically acceptable salt thereof or a stereoisomer thereof: wherein R1, R2, R3 and R4 are as defined in any one of claims 1 to 3; X2 is H, OH or -N(Rho)(R7); R6 is H or C1-4 alkyl; R7 is H or Rs-S(O)2-; Rs is C1-4 alkyl; eq is 0, 1, 2, 3 or 4. Petition 870250101738, dated 06 / 11 / 2025, p. 59 / 273 5 / 7 13. A compound, pharmaceutically acceptable salt thereof or stereoisomer thereof, according to claim 12, characterized in that R1 is methyl and R2 is H, Cl or F; or R1 and R2 are cyclized to form -O-(CH2)mO- in R1 or R2.

14. A compound, pharmaceutically acceptable salt thereof or stereoisomer thereof, according to claim 12 or 13, characterized in that R3 and R4 are both H; or R3 is H and R4 is methyl.

15. A compound, pharmaceutically acceptable salt thereof, or stereoisomer thereof, according to any one of claims 12 to 14, characterized in that X2 is H eq is 0; or X2 is OH or -N(R6)(R7) eq is 0, 1, 2, 3 or 4; or X2 is OH or N(R6)(R7), q is 0, 1, 2, 3 or 4, R3 and R4 are both H, R1 is methyl and R2 is H, Cl or F or R1 and R2 are cyclized to form -O-(CH2)mO-, wherein m is 1 or 2; or X2 is H, OH, NH2 or N(i-Pr)-S(O)2-CH3.

16. Compound, pharmaceutically acceptable salt thereof or stereoisomer thereof, according to any one of claims 12 to 15, characterized in that Formula IIb is a compound of Formula IIb-1 or Formula IIb-2, a pharmaceutically acceptable salt thereof or a stereoisomer thereof; Formula IIb-1 where Ri, R2, X2 eq are as defined in any one of claims 12 to 13 and 15.

17. Compound, pharmaceutically acceptable salt thereof or stereoisomer thereof, according to claim 5 or 12, characterized in that the compound of Formula IIa is the following compound, a pharmaceutically acceptable salt thereof or a stereoisomer thereof: Petition 870250101738, dated 06 / 11 / 2025, p. 60 / 273 6 / 7 Formula IIb is the following compound, a pharmaceutically acceptable salt thereof or a stereoisomer thereof: Petition 870250101738, dated 06 / 11 / 2025, p. 61 / 273 7 / 7 18. Pharmaceutical composition, characterized in that it comprises the compound, a pharmaceutically acceptable salt thereof or a stereoisomer thereof, as defined in any one of claims 1 to 17, and a pharmaceutically acceptable excipient.

19. Use of the compound, of the pharmaceutically acceptable salt thereof or of the stereoisomer thereof, as defined in any one of claims 1 to 17, or of the pharmaceutical composition, as defined in claim 18, characterized in that it is used in the manufacture of a medicament for the treatment of tumors. Petition 870250101738, dated 06 / 11 / 2025, pp. 62 / 273